Developer docs
API playgroundTry for free, no card

Search company profiles

Gland Pharma

Full company profile

uuid00009oe

Namestring
Gland Pharma
Legal namestring
Gland Pharma Limited
Websiteurl
glandpharma.com
Company typeenum
Public
Founded yearint
1978
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic injectable pharmaceuticals, sterile injectables manufacturing, contract development manufacturing, active pharmaceutical ingredients, ophthalmic injectable products
Industry5 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Injectable Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Generic Injectables Manufacturing and Sales
TypeOne Time License
Description

Manufacture and sale of generic injectable pharmaceuticals including sterile injectables, oncology drugs, and ophthalmic products to global pharmaceutical companies and healthcare providers.

glandpharma.com
2Contract Development and Manufacturing (CDMO)
TypeManaged Services
Description

CDMO services for other pharmaceutical companies, offering contract manufacturing, technology transfer, and development services. The CDMO segment contributed nearly half of consolidated revenue and grew 28% in FY26.

glandpharma.com
3API (Active Pharmaceutical Ingredient) Manufacturing
TypeOne Time License
Description

In-house manufacturing of APIs providing backward integration and supply chain control, supporting 32 ANDAs with in-house API capabilities.

glandpharma.com
4Technology Transfer Services
TypeProfessional Services
Description

Technology transfer projects where customers transfer technology to Gland Pharma for manufacturing, involving technical gap analysis, analytical method transfers, and validation.

economictimes.indiatimes.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gland Pharma manufactures and supplies generic injectable pharmaceuticals including sterile injectables, oncology injectables, and ophthalmic products across 60+ countries. The company operates four cGMP-compliant formulation facilities and four API facilities in India, supported by two R&D divisions in Hyderabad with nearly 300 scientists. It also offers Contract Development and Manufacturing Organization (CDMO) services encompassing formulation development, analytical method development, API process development, and technology transfer, with European operations delivered through its acquired subsidiary Cenexi Group.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Revenue grew 32% to ₹34,629 million in FY2020-21
+6 more records
Product overview1 text field

Gland Pharma is a global injectable-focused pharmaceutical company operating primarily under a B2B (business-to-business) model. The company offers a vertically integrated portfolio combining Contract Development and Manufacturing Organization (CDMO) services with proprietary generic injectable products. The core offerings include sterile injectables manufacturing (solutions, lyophilized products, suspensions, pre-filled syringes), API manufacturing for backward integration, oncology injectables, and ophthalmic products. Their CDMO services encompass formulation development, analytical method development, API process development, and technology transfer capabilities. The company operates 4 formulation facilities and 4 API facilities in India, with European operations through acquired subsidiary Cenexi Group. They focus on complex injectables, First-to-File products, and 505(b)(2) filings with regulatory approvals from USFDA, MHRA, ANVISA, TGA, and other agencies.

Product and service8 records
1Contract Development and Manufacturing Organization (CDMO) Services
CategoryCDMO Services
Description

Comprehensive CDMO services for sterile injectables, including formulation development, analytical method development, API process development, stability studies, technology transfer, and contract manufacturing for global pharmaceutical partners.

2Sterile Injectables Manufacturing
CategorySterile Injectables
Description

Manufacturing of sterile injectable products including solutions, suspensions, lyophilized products, pre-filled syringes, vials, ampoules, bags, and dry powder injections using aseptic filling or terminal sterilization.

3Generic Injectables Portfolio
CategoryGeneric Injectables
Description

Broad portfolio of generic injectable medications including complex generic injectables, NCE-1s, First-to-File products, and 505(b)(2) filings for regulated markets.

4Active Pharmaceutical Ingredients (API) Manufacturing
CategoryAPI Manufacturing
Description

In-house API manufacturing across four facilities enabling backward integration and supply chain control, particularly for difficult-to-source APIs including low molecular weight heparins, steroids, and oncology drugs.

5Oncology Injectables
CategoryOncology Injectables
Description

Specialized oncology injectable manufacturing including products for multiple myeloma treatment and solid tumor applications, produced at a dedicated oncology facility.

6Ophthalmic Products
CategoryOphthalmic Products
Description

Ophthalmic solutions and products including prescription and OTC eye drops for conditions such as allergic conjunctivitis and eye redness relief.

7Penems Injectables
CategoryPenems / Beta-Lactam Antibiotics
Description

Dedicated Penems facility for manufacturing of beta-lactam antibiotic injectables.

8Cenexi Group European CDMO Services
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Collaboration for FDA-approved generic Infuvite Pediatric Injection. The program involved combined scientific, regulatory, and manufacturing capabilities of Apotex, Orbicular Pharmaceutical Technologies, and Gland Pharma. Apotex serves as the ANDA sponsor leading US commercialization while Gland Pharma provides manufacturing capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-29
Description

Gland Pharma acquired 100% stake in French CDMO Cenexi Group for up to Euro 120 million (approximately ₹1,015 crore). Cenexi specializes in sterile injectable drug development and manufacturing, expanding Gland Pharma's European presence and CDMO capabilities. The acquisition was completed in April 2023.

Strategic tierMinorTypeOthers
Description

Partnership for the Free Breakfast Scheme serving nearly 9,100 children of 66 government-run schools around Gland Pharma's manufacturing facilities in Hyderabad and Visakhapatnam. Akshaya Patra prepares and supplies nutritious breakfast, with Gland Pharma providing funding support.

Strategic tierMinorTypeOthers
Description

Healthcare partnership for eye care. Gland Pharma contributed to LVPEI for PPE kits and medical supplies during COVID-19, and funding for setting up a dedicated 'Centre for Elderly Eye Care' at Hyderabad.

5Swayamkrushi
Strategic tierMinorTypeOthers
Description

Hyderabad-based NGO sheltering mentally challenged women. Gland Pharma contributed to construction of a Vocational Training Centre-cum-Residential Block and procurement of jute bag-making machines for vocational training.

glandpharma.com
6Nehru Zoological Park
Strategic tierMinorTypeOthers
Description

Wildlife conservation partnership. Gland Pharma contributed ₹20 lakh to Nehru Zoological Park for adoption of animals and birds, and ₹20 lakh for kangaroo fence construction.

glandpharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sun Pharmaceutical Industries
TypeDirect peer
Description

India's largest pharmaceutical company with a meaningful specialty injectables portfolio and US generics presence. Overlaps with Gland in sterile injectables and complex generics categories across regulated markets.

TypeDirect peer
Description

India-based CDMO with injectable manufacturing capabilities and complex API services. Operates in the same customer segments as Gland's CDMO business and shares the Indian manufacturing and regulatory footprint.

TypeDirect peer
Description

Indian pharmaceutical major with growing injectables and complex generics capabilities. Has comparable US ANDA presence and is investing in sterile injectable capacity, making it a relevant peer for Gland's core business.

TypeDirect peer
Description

Large Indian generic pharmaceutical manufacturer with a significant sterile injectables portfolio and US ANDA presence. Competes directly with Gland in US generic injectables and shares the Hyderabad manufacturing base, making it the closest head-to-head comparator.

TypeDirect peer
Description

India-headquartered global pharmaceutical company with a substantial sterile injectables franchise and CDMO services. Operates in overlapping US, EU, and emerging markets with comparable complex injectable capabilities and API integration.

6Recipharm
TypeDirect peer
Description

European CDMO with sterile injectable capabilities acquired by EQT-owned consortium. Provides the most direct European CDMO comparable to Gland's newly acquired Cenexi operations in terms of service offering and customer base.

TypeDirect peer
Description

Major China-based CDMO with growing sterile injectable and small-molecule API capabilities. Competes with Gland in API and injectable CDMO, with comparable scale and complexity though different geographic risk profile.

TypeBroad incumbent
Description

Pharmaceutical contract manufacturing arm of Baxter focused on sterile injectables and parenteral products. Provides CDMO services for complex injectables, overlapping with Gland's high-potency and lyophilized product capabilities.

TypeDirect peer
Description

Global CDMO with deep sterile injectable and parenteral drug product capabilities serving branded biopharma. Closely comparable to Gland's CDMO segment in terms of technology and customer profile, though predominantly serving innovator pharma rather than generics.

10Hospira (Pfizer CentreOne)
TypeBroad incumbent
Description

Pfizer's CDMO arm and the largest US sterile injectables manufacturer. Competes broadly with Gland in the US injectable supply market and provides CDMO services for complex parenteral products, though it operates at much larger scale across a broader portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gland Pharma

Generic Injectable Pharmaceuticalsglandpharma.com

Gland Pharma firmographics

Firmographics
Name
Gland Pharma
Legal name
Gland Pharma Limited
Website
https://glandpharma.com
Company type
Public
Founded year
1978
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Gland Pharma industry classification

Industry
Product category
Generic Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Generic injectable pharmaceuticals
  • Sterile injectables manufacturing
  • Contract development manufacturing
  • Active pharmaceutical ingredients
  • Ophthalmic injectable products

Where Gland Pharma is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices5 records

Markets served

Gland Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Generic Injectables Manufacturing and Sales: Manufacture and sale of generic injectable pharmaceuticals including sterile injectables, oncology drugs, and ophthalmic products to global pharmaceutical companies and healthcare providers.
  2. Contract Development and Manufacturing (CDMO): CDMO services for other pharmaceutical companies, offering contract manufacturing, technology transfer, and development services. The CDMO segment contributed nearly half of consolidated revenue and grew 28% in FY26.
  3. API (Active Pharmaceutical Ingredient) Manufacturing: In-house manufacturing of APIs providing backward integration and supply chain control, supporting 32 ANDAs with in-house API capabilities.
  4. Technology Transfer Services: Technology transfer projects where customers transfer technology to Gland Pharma for manufacturing, involving technical gap analysis, analytical method transfers, and validation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Gland Pharma product offering

Product offering

Core offering

Gland Pharma manufactures and supplies generic injectable pharmaceuticals including sterile injectables, oncology injectables, and ophthalmic products across 60+ countries. The company operates four cGMP-compliant formulation facilities and four API facilities in India, supported by two R&D divisions in Hyderabad with nearly 300 scientists. It also offers Contract Development and Manufacturing Organization (CDMO) services encompassing formulation development, analytical method development, API process development, and technology transfer, with European operations delivered through its acquired subsidiary Cenexi Group.

Product overview

Gland Pharma is a global injectable-focused pharmaceutical company operating primarily under a B2B (business-to-business) model. The company offers a vertically integrated portfolio combining Contract Development and Manufacturing Organization (CDMO) services with proprietary generic injectable products. The core offerings include sterile injectables manufacturing (solutions, lyophilized products, suspensions, pre-filled syringes), API manufacturing for backward integration, oncology injectables, and ophthalmic products. Their CDMO services encompass formulation development, analytical method development, API process development, and technology transfer capabilities. The company operates 4 formulation facilities and 4 API facilities in India, with European operations through acquired subsidiary Cenexi Group. They focus on complex injectables, First-to-File products, and 505(b)(2) filings with regulatory approvals from USFDA, MHRA, ANVISA, TGA, and other agencies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Contract Development and Manufacturing Organization (CDMO) Services Comprehensive CDMO services for sterile injectables, including formulation development, analytical method development, API process development, stability studies, technology transfer, and contract manufacturing for global pharmaceutical partners.
  • Sterile Injectables Manufacturing Manufacturing of sterile injectable products including solutions, suspensions, lyophilized products, pre-filled syringes, vials, ampoules, bags, and dry powder injections using aseptic filling or terminal sterilization.
  • Generic Injectables Portfolio Broad portfolio of generic injectable medications including complex generic injectables, NCE-1s, First-to-File products, and 505(b)(2) filings for regulated markets.
  • Active Pharmaceutical Ingredients (API) Manufacturing In-house API manufacturing across four facilities enabling backward integration and supply chain control, particularly for difficult-to-source APIs including low molecular weight heparins, steroids, and oncology drugs.
  • Oncology Injectables Specialized oncology injectable manufacturing including products for multiple myeloma treatment and solid tumor applications, produced at a dedicated oncology facility.
  • Ophthalmic Products Ophthalmic solutions and products including prescription and OTC eye drops for conditions such as allergic conjunctivitis and eye redness relief.
  • Penems Injectables Dedicated Penems facility for manufacturing of beta-lactam antibiotic injectables.
  • Cenexi Group European CDMO Services

Quantifiable outcome

  • Revenue grew 32% to ₹34,629 million in FY2020-21
  • +6 more outcomes

Companies that use Gland Pharma

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Gland Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Gland Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Apotex Inc.coreStrategic or Co-development Partner · 27 April 2026Collaboration for FDA-approved generic Infuvite Pediatric Injection. The program involved combined scientific, regulatory, and manufacturing capabilities of Apotex, Orbicular Pharmaceutical Technologies, and Gland Pharma. Apotex serves as the ANDA sponsor leading US commercialization while Gland Pharma provides manufacturing capabilities.
  • Cenexi Group (Acquired)coreStrategic or Co-development Partner · 29 November 2022Gland Pharma acquired 100% stake in French CDMO Cenexi Group for up to Euro 120 million (approximately ₹1,015 crore). Cenexi specializes in sterile injectable drug development and manufacturing, expanding Gland Pharma's European presence and CDMO capabilities. The acquisition was completed in April 2023.
  • Akshaya Patra FoundationminorOthersPartnership for the Free Breakfast Scheme serving nearly 9,100 children of 66 government-run schools around Gland Pharma's manufacturing facilities in Hyderabad and Visakhapatnam. Akshaya Patra prepares and supplies nutritious breakfast, with Gland Pharma providing funding support.
  • LV Prasad Eye Institute (LVPEI)minorOthersHealthcare partnership for eye care. Gland Pharma contributed to LVPEI for PPE kits and medical supplies during COVID-19, and funding for setting up a dedicated 'Centre for Elderly Eye Care' at Hyderabad.
  • SwayamkrushiminorOthersHyderabad-based NGO sheltering mentally challenged women. Gland Pharma contributed to construction of a Vocational Training Centre-cum-Residential Block and procurement of jute bag-making machines for vocational training.
  • Nehru Zoological ParkminorOthersWildlife conservation partnership. Gland Pharma contributed ₹20 lakh to Nehru Zoological Park for adoption of animals and birds, and ₹20 lakh for kangaroo fence construction.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Gland Pharma competitors and assessment

Company assessment

Direct peers

  • Sun Pharmaceutical Industries: India's largest pharmaceutical company with a meaningful specialty injectables portfolio and US generics presence. Overlaps with Gland in sterile injectables and complex generics categories across regulated markets.
  • Piramal Pharma Solutions: India-based CDMO with injectable manufacturing capabilities and complex API services. Operates in the same customer segments as Gland's CDMO business and shares the Indian manufacturing and regulatory footprint.
  • Cipla: Indian pharmaceutical major with growing injectables and complex generics capabilities. Has comparable US ANDA presence and is investing in sterile injectable capacity, making it a relevant peer for Gland's core business.
  • Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with a significant sterile injectables portfolio and US ANDA presence. Competes directly with Gland in US generic injectables and shares the Hyderabad manufacturing base, making it the closest head-to-head comparator.
  • Dr. Reddy's Laboratories: India-headquartered global pharmaceutical company with a substantial sterile injectables franchise and CDMO services. Operates in overlapping US, EU, and emerging markets with comparable complex injectable capabilities and API integration.
  • Recipharm: European CDMO with sterile injectable capabilities acquired by EQT-owned consortium. Provides the most direct European CDMO comparable to Gland's newly acquired Cenexi operations in terms of service offering and customer base.
  • WuXi STA: Major China-based CDMO with growing sterile injectable and small-molecule API capabilities. Competes with Gland in API and injectable CDMO, with comparable scale and complexity though different geographic risk profile.
  • Catalent: Global CDMO with deep sterile injectable and parenteral drug product capabilities serving branded biopharma. Closely comparable to Gland's CDMO segment in terms of technology and customer profile, though predominantly serving innovator pharma rather than generics.

Broad incumbents

  • Baxter BioPharma Solutions: Pharmaceutical contract manufacturing arm of Baxter focused on sterile injectables and parenteral products. Provides CDMO services for complex injectables, overlapping with Gland's high-potency and lyophilized product capabilities.
  • Hospira (Pfizer CentreOne): Pfizer's CDMO arm and the largest US sterile injectables manufacturer. Competes broadly with Gland in the US injectable supply market and provides CDMO services for complex parenteral products, though it operates at much larger scale across a broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Gland Pharma social profiles

Digital presence

Gland Pharma compliance and trust

Trust signal

Compliance8 records

Gland Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gland Pharma leadership team

Management profile

Number of profiles

Profiles17 records

Gland Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Gland Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gland Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gland Pharma

What does Gland Pharma do?

Gland Pharma manufactures and supplies generic injectable pharmaceuticals including sterile injectables, oncology injectables, and ophthalmic products across 60+ countries. The company operates four cGMP-compliant formulation facilities and four API facilities in India, supported by two R&D divisions in Hyderabad with nearly 300 scientists. It also offers Contract Development and Manufacturing Organization (CDMO) services encompassing formulation development, analytical method development, API process development, and technology transfer, with European operations delivered through its acquired subsidiary Cenexi Group.

Is Gland Pharma a public or private company?

Gland Pharma is a public company. It is classified as public and is currently operating.

When was Gland Pharma founded?

Gland Pharma was founded in 1978. It employs 1,001 to 5,000 people.

Where is Gland Pharma based?

Gland Pharma is headquartered in Hyderabad, India, in the Asia region.

How does Gland Pharma make money?

Four revenue lines are on record. Generic Injectables Manufacturing and Sales are the primary driver. The others are contract Development and Manufacturing (CDMO), API (Active Pharmaceutical Ingredient) Manufacturing and technology Transfer Services.

Who are Gland Pharma's main competitors?

Direct peers on record are Sun Pharmaceutical Industries, Piramal Pharma Solutions, Cipla, Aurobindo Pharma, Dr. Reddy's Laboratories, Recipharm, WuXi STA and Catalent. Broad incumbents are Baxter BioPharma Solutions and Hospira (Pfizer CentreOne).

Does Gland Pharma have an API?

No public API is recorded for Gland Pharma.

What industry is Gland Pharma in?

Gland Pharma's product category is Generic Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MintLaurus Labs, Gland Pharma, Piramal, Divi's Labs: 4 drug manufacturing stocks rally up to 89% in 6 months - Upside ahead? | Stock Market NewsLaurus Labs, Gland Pharma, Piramal Pharma, and Divi's Laboratories have rallied up to 89% over six months. Laurus gained 88.64% to ₹2,395.10, Gland 80.36% to ₹3,307.50, Divi's 72.35% to ₹11,450, and Piramal 38.65% to ₹245. Analysts set target prices, with Divi's already surpassing ICICI and Motilal Oswal's targets.Simply Wall St₹3,165 - That's What Analysts Think Gland Pharma Limited (NSE:GLAND) Is Worth After These ResultsGland Pharma reported Q2 revenue of ₹18b, beating forecasts by 3.8%, with statutory EPS of ₹17.62, up 2.8%. Analysts reconfirmed 2027 revenue and EPS forecasts, but raised the price target to ₹3,165, a 6.8% increase. The company is expected to grow revenue at 15% annually, matching industry pace.The Times of IndiaGland Pharma names Xiao Le CIO to strengthen global M&A capabilitiesGland Pharma appointed Xiao Le as chief investment officer of its Singapore subsidiary, effective November 9. He will focus on identifying investment opportunities and strengthening M&A capabilities in the US, China, Singapore, and other markets. Le brings over 15 years of experience in investment and asset management.Business News TodayGland Pharma shares rally 8% to hit 4-year-high post strong Q2; what brokerages say, check target prices- Moneycontrol.comGland Pharma shares rose nearly 8% to a four-year high of Rs 3,374 after reporting a 58.29% net profit increase to Rs 290.75 crore in Q2 FY27. Brokerages are split, with Motilal Oswal and Axis Direct maintaining Buy ratings, while Elara Capital downgraded to Sell.CNBCTV18Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell' - CNBC TV18Gland Pharma shares rose 7% to a 52-week high after reporting a 58.2% year-on-year net profit increase to ₹291 crore in Q2FY27. Nomura sees a re-rating opportunity, while Citi maintains a 'Sell' rating. The company guided for 15% FY27 revenue growth and targets a 20% CAGR over four years.Zee BusinessPharma Stocks Rally! Nifty Pharma hits 52-week high, gains 27% in 2026, outperforms Nifty 50 – What's driving rally?Pharmaceutical stocks rallied on November 9, with the Nifty Pharma index hitting a fresh 52-week high after Q2 FY27 earnings. The index gained 1.39% to 28,822.80, while top gainers included Gland Pharma and Sai Life Sciences. The index has outperformed the Nifty 50 over multiple periods.Business StandardPharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Pharma stocks including Divi's, Laurus, Sai, Gland, and Glenmark rose 5-9% on the NSE after strong Q2 earnings. The Nifty Pharma index hit a new high of 29,224.85, up 3%, while analysts set price targets for Divi's and Sai Life Sciences.Zee BusinessGland Pharma shares hit 52-week high: Latest news and key levels to trackGland Pharma shares rose nearly 8% on Monday, hitting a 52-week high of Rs 3,372, surpassing an earlier peak of Rs 3,209. The company appointed Xiao Le as Chief Investment Officer for its subsidiary Gland Pharma International Pte, effective immediately, to explore investment opportunities and improve M&A capability in the US, China, and Singapore.Business TodayDivis Laboratories, Gland Pharma, Sai Life Sciences shares hit 52 week highs; here's why - BusinessTodayShares of Divis Laboratories, Gland Pharma, and Sai Life Sciences hit 52-week highs on Monday after Divis Labs reported Q2 earnings. Divis Labs' net profit rose 64% to Rs 1,127 crore, while Gland Pharma's profit increased 58.2% to Rs 291 crore. The rally was driven by strong quarterly results across the three firms.MintGland Pharma shares hit 52-week high; jump 7% despite market sell-off | Will rally continue after 93% YTD rise? | Stock Market NewsGland Pharma shares rose over 6.7% to a 52-week high on Monday, defying a market sell-off. The company reported a 58.2% year-on-year net profit jump to ₹291 crore for Q2 FY27, with revenue up 23.3% to ₹1,834 crore. Analysts maintain a buy rating with a ₹3,690 target.